XBIT Stock Overview
A biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
XBiotech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.50 |
| 52 Week High | US$9.96 |
| 52 Week Low | US$3.83 |
| Beta | 1.34 |
| 1 Month Change | -34.11% |
| 3 Month Change | -33.23% |
| 1 Year Change | 14.80% |
| 3 Year Change | -59.50% |
| 5 Year Change | -76.80% |
| Change since IPO | -80.18% |
Recent News & Updates
Is XBiotech (NASDAQ:XBIT) Weighed On By Its Debt Load?
Aug 30
XBiotech: Several Shots On Goal In Big Target Market Indications
May 24Is XBiotech (NASDAQ:XBIT) Using Debt In A Risky Way?
May 13Recent updates
Is XBiotech (NASDAQ:XBIT) Weighed On By Its Debt Load?
Aug 30XBiotech: Several Shots On Goal In Big Target Market Indications
May 24Is XBiotech (NASDAQ:XBIT) Using Debt In A Risky Way?
May 13We're Not Very Worried About XBiotech's (NASDAQ:XBIT) Cash Burn Rate
Feb 09We're Hopeful That XBiotech (NASDAQ:XBIT) Will Use Its Cash Wisely
Oct 25We Think Some Shareholders May Hesitate To Increase XBiotech Inc.'s (NASDAQ:XBIT) CEO Compensation
Jun 16XBiotech (NASDAQ:XBIT) Is In A Good Position To Deliver On Growth Plans
May 11Read This Before Buying XBiotech Inc. (NASDAQ:XBIT) Shares
Mar 18Here's Why We Don't Think XBiotech's (NASDAQ:XBIT) Statutory Earnings Reflect Its Underlying Earnings Potential
Jan 08XBiotech's influenza-COVID-19 therapeutic cocktail shows effective anti-virus activity
Nov 19Shareholder Returns
| XBIT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -35.0% | -3.8% | -2.7% |
| 1Y | 14.8% | -2.6% | 23.4% |
Return vs Industry: XBIT exceeded the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: XBIT underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| XBIT volatility | |
|---|---|
| XBIT Average Weekly Movement | 9.6% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: XBIT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: XBIT's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 92 | John Simard | www.xbiotech.com |
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.
XBiotech Inc. Fundamentals Summary
| XBIT fundamental statistics | |
|---|---|
| Market cap | US$194.48m |
| Earnings (TTM) | -US$32.66m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.2x
P/E RatioIs XBIT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XBIT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$32.66m |
| Earnings | -US$32.66m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.07 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 5.2% |
How did XBIT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 23:18 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
XBiotech Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kumaraguru Raja | NOBLE Capital Markets, Inc. |
| Joseph Catanzaro | Piper Sandler Companies |